CurrentUnitedHealthcarePolicy CS031KY.06

Discogenic Pain Treatment (for Kentucky Only)

Medical policy governing coverage and medical necessity determinations for procedures to treat discogenic low back pain in Kentucky, including annular closure devices, percutaneous intradiscal thermal procedures, and percutaneous injections of allogeneic cellular/tissue-based products. Affects providers and members covered under UnitedHealthcare in Kentucky.

Policy Summary

PayerUnitedHealthcare

PolicyDiscogenic Pain Treatment (for Kentucky Only)

Policy CodePolicy CS031KY.06

Change TypeCoding and evidence updates

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain benefit verification and prior authorization as required by the member's contract for listed procedures and codes.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect annual edits; added 63032

Updated Clinical Evidence and References sections to reflect the most current information

3procedures unproven / not medically necessary

0627T-0630TT-codes for allogeneic injections

22526-22899,63032,S2348Relevant CPT/HCPCS codes

Kentucky-onlyjurisdiction

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

FDA approval (Barricaid)

Coverage Criteria and Rationale

Unproven / Not Medically Necessary

The following are considered unproven and not medically necessary:

Annular closure devices (ACDs) are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Hayes and ECRI reviews found low-quality evidence, small studies, and methodological limitations; see clinical evidence summary.

Percutaneous injection of allogeneic cellular/tissue-based products for discogenic pain is considered unproven and not medically necessary due to insufficient high-quality evidence.

Randomized trials and feasibility studies are limited and inconsistent; robust RCTs with larger samples and long-term outcomes are needed.

Thermal intradiscal procedures (TIPs): Thermal intradiscal procedures (including IDET, IDB, PIRFT) are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Systematic reviews and RCTs show mixed results and methodological limitations; PIRFT RCTs did not demonstrate clear benefit over sham.

Coverage summary by technology

Coverage stance based on available evidence

Annular Closure Devices (ACDs): Randomized trials report reduced recurrent herniation and reoperation with bone-anchored ACDs versus discectomy alone, but overall evidence quality is low and further RCTs are needed; limitations include small studies, potential conflicts of interest, and limited long-term data.

See systematic assessments and Hayes conclusions regarding low-quality evidence and study limitations.

Percutaneous intradiscal allogeneic cellular/tissue-based products: Current evidence is insufficient to support use for discogenic pain; available RCTs and feasibility studies are limited, inconsistent, and do not establish clear long-term benefit.

Policy cites need for robust RCTs with larger samples and long-term outcomes.

Thermal intradiscal procedures (IDET/IDB/PIRFT): Evidence is mixed: some RCTs and smaller trials suggest benefit for select techniques (e.g., biacuplasty), but PIRFT RCTs did not show benefit over sham and overall evidence is inadequate to support routine use.

Guideline and trial limitations (small sample sizes, lack of sham controls, inconsistent findings) are cited.

Evidence synthesis and guideline positions

Evidence and guideline conclusions summarized:

Evidence from small studies: Small case series and pilot studies report improvements in pain and function (examples include bipolar RFTC case series n=23 and L'DISQ pilot n=20) but are limited by small size and lack of controls.

See Zhang 2016 and Lee 2015 case series reports.

Randomized trial outcome for PIRFT: A double-blind RCT (Kvarstein 2009, n=20) found no significant benefit of PIRFT versus sham at six months and no between-group difference at 12 months; authors did not recommend intra-annular discTRODE therapy based on these results.

Kvarstein RCT concluded lack of evidence for benefit.

Guideline assessments: Society and guideline reviews conclude evidence is limited or inconsistent: ASIPP rated intradiscal electrothermal therapy evidence as limited/fair; NICE found efficacy evidence inconsistent/poor quality and encouraged further research; NASS found insufficient evidence to recommend for or against PIRFT.

Policy cites ASIPP, NICE, and NASS guideline statements.

Annular closure device

Device-specific coverage-relevant information:

Barricaid FDA indication: The Barricaid annular closure device received FDA premarket approval (Feb 8, 2019) for reducing reherniation and reoperation in skeletally mature patients with radiculopathy attributed to a posterior or posterolateral herniation and a large annular defect (4–6 mm tall and 6–10 mm wide) following primary discectomy at a single level between L4 and S1.

FDA approval is informational only; coverage decisions reference this indication and require documentation of imaging, defect size, and clinical findings.

For percutaneous discectomy performed for axial or radicular pain, refer to the UnitedHealthcare Medical Policy titled Minimally Invasive Spine Surgery Procedures (Kentucky only) for coverage and medical necessity guidance.

Examples of procedures for which there is insufficient high-quality evidence to support use for discogenic low back pain include: percutaneous injection of allogeneic cellular/tissue-based products and thermal intradiscal procedures (including IDET, IDB, and PIRFT).

Randomized controlled trial evidence for intra‑annular radiofrequency thermocoagulation (PIRFT with the discTRODE probe) did not demonstrate benefit over sham in a double‑blind RCT and the study authors did not recommend routine use; guideline assessments (NICE) similarly describe the evidence as limited in quantity and poor or inconsistent in quality and call for further research with clearer patient selection and long‑term follow‑up.

Annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue‑based products, and thermal intradiscal procedures are considered unproven technologies for treating discogenic low back pain because current evidence is limited, of low quality, or inconsistent regarding safety and efficacy.

When the available evidence is judged to be insufficient to demonstrate safety and efficacy, these interventions are classified as not medically necessary and are not supported for routine coverage.

The randomized, double‑blind placebo RCT of PIRFT (Kvarstein et al. 2009) showed no significant difference between active and sham treatment at planned interim analysis and no durable between‑group benefit at 12 months; guideline reviews (NICE) characterize the efficacy evidence as limited and inconsistent, supporting non‑coverage of routine intra‑annular PIRFT.

Coding and Procedure Codes

Percutaneous injection of allogeneic cellular/tissue-based products (T-codes)CPTNot Covered

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).

Intradiscal thermal procedures and related spine procedure codesCPT | HCPCS

22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure).
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar.

Applicable CPT Codes (updated)CPT

63032

code added to applicable CPT codes (document notes annual edits)

FDA device approvals / product codesmixed

PMA K201676

Barricaid Annular Closure Device premarket approval reference

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Code List

Providers should obtain benefit verification and prior authorization when billing for the procedures and codes listed in this policy. Prior authorization helps confirm member coverage, medical necessity, and any applicable plan or state-specific requirements before services are rendered.

Verify benefits and obtain prior authorization per payer rules before scheduling procedures
Include applicable procedure codes listed in the policy when requesting authorization

Prior Authorization

Prior Authorization Recommended for Intradiscal Allografts

Prior authorization is recommended for intradiscal allograft injections given limited and inconsistent trial evidence. Requests should include detailed clinical documentation of conservative management and trial outcomes to support medical necessity.

Intradiscal allograft codes (e.g., 0627T–0630T) are subject to review
Provide prior authorization documentation of failed conservative care and trial enrollment/outcomes

Background and Scope

Discogenic low back pain is thought to originate from degenerative changes in the intervertebral disc and from annular disruption. Treatments such as annular repair devices, intradiscal biologics, and thermal intradiscal techniques aim to reduce pain or prevent reherniation by modifying disc tissue or closing annular defects, but the clinical rationale must be supported by high‑quality evidence demonstrating improved patient‑reported outcomes and acceptable safety.

Definitions

Annulus fibrosus / annular closure device — definition and device intent

Annulus fibrosusRing of fibrocartilage and fibrous tissue surrounding the nucleus pulposus; repair devices aim to reinforce or bridge the annular defect.

Annular closure device (general intent)Implantable repair material or device intended to close or reinforce an annular defect created by discectomy and to form a barrier between the nucleus and annulus to reduce reherniation risk.

Use contextPlaced at time of discectomy or during spine surgery to repair the annulus fibrosus defect and restore a stronger, flexible annular wall.

Thermal Intradiscal Procedures (TIPs), IDET, IDB, PIRFT — definitions and procedural description

Thermal Intradiscal Procedures (TIPs)Percutaneous insertion of a catheter or probe into the disc under fluoroscopic guidance to apply heat within the disc aiming to relieve low back pain by tissue modification and denervation.

Required Conservative Care Prior to Procedures

Failure of conservative care commonly required in studies — >6 weeks

Failure of conservative care commonly required in study populations prior to surgical interventions:

Conservative care before ACD studies: >6 weeks of failed conservative care was commonly required for patients enrolled in ACD studies (or contraindications to conservative strategies such as neurological deficits).>6 weeks

Hayes assessment noted most included patients had failed >6 weeks of conservative care.

Failure of conservative management prior to considering intradiscal procedures — >= 3 months

Failure of conservative management prior to considering intradiscal procedures:

Minimum conservative management duration: Studies of intradiscal procedures generally included patients with at least three months of conservative treatment before intervention.

Frequency and Use Limitations

Barricaid intended use — placement at time of primary single-level discectomy

Intended use — BarricaidPlacement of the Barricaid annular closure device is indicated at the time of primary single-level discectomy to reduce incidence of reherniation and reoperation in skeletally mature patients with radiculopathy and a large annular defect.

Defect and level specificationsIndication specifies a large annular defect (about 4–6 mm tall and 6–10 mm wide) following primary discectomy at a single level between L4 and S1.

Context in evidenceRCTs of bone-anchored ACDs evaluated placement at discectomy with observed reductions in reherniation and reoperation rates versus discectomy alone.

Imaging and Procedural Guidance

Documentation Required

Use fluoroscopic (or CT) guidance per procedure

Perform TIPs, IDET, IDB, PIRFT, and percutaneous intradiscal injections under fluoroscopic guidance (or CT guidance for injections when described) as specified for each procedure.

TIPs generally involve catheter or probe insertion under fluoroscopic guidance.
Some intradiscal injections are described with CT guidance (see T-code descriptions).

Documentation Required

Use MRI and discography findings for IDB/IDET patient selection

Patient selection for IDB/IDET commonly relies on MRI and discography findings (e.g., disc degeneration at ≤3 levels, preserved disc height >50%, presence of high-intensity zone, or positive provocation discography) to support the procedure.

Studies reported inclusion criteria such as disc height preservation >50% and positive reproducible pain on discography.
Presence of HIZ on MRI and high-grade DDS predicted better outcomes in some series.

Services Not Covered / Exclusions

The following technologies are listed as NOT COVERED due to insufficient or inconclusive evidence: annular closure devices (ACDs); percutaneous injection of allogeneic cellular/tissue‑based products; and thermal intradiscal procedures (e.g., IDET, IDB, PIRFT).

Annular closure devices, percutaneous intradiscal allogeneic cellular/tissue‑based injections, and thermal intradiscal procedures are identified in this policy as not covered because current studies do not provide sufficient high‑quality evidence of net clinical benefit.

These interventions — annular closure devices, allogeneic intradiscal injections, and thermal intradiscal techniques — remain not covered in the absence of robust randomized evidence demonstrating safety and effectiveness.

Percutaneous injection of allogeneic cellular/tissue‑based products and thermal intradiscal procedures are specifically noted as having insufficient evidence to support routine use and therefore are considered investigational or not medically necessary.

The policy classifies annular closure devices, percutaneous allogeneic disc injections, and thermal intradiscal procedures as not covered based on the current evidence base which is inadequate to establish clinical benefit.

Providers should note that annular closure devices, intradiscal biologic injections using allogeneic products, and intradiscal thermal therapies are all considered not covered under this policy due to insufficient supporting evidence.

Policy Summary

PayerUnitedHealthcare

PolicyDiscogenic Pain Treatment (for Kentucky Only)

Policy CodePolicy CS031KY.06

Change TypeCoding and evidence updates

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain benefit verification and prior authorization as required by the member's contract for listed procedures and codes.

SourceLink

On This Page

Billing Rule

Applicable CPT Code Update

The policy was updated to add CPT code 63032 to the applicable code list. Follow UnitedHealthcare and contract-specific rules for prior authorization and billing for this code.

Added CPT 63032 — Laminotomy with repair of annular defect by implantation of bone-anchored annular closure device
Follow payer-specific authorization and documentation requirements when submitting claims for 63032

Denial Risk

Denial Risk for Unproven Procedures

Procedures identified in this policy as unproven or not medically necessary (for example, some annular closure approaches or percutaneous allogeneic injections without sufficient evidence) may be denied if documentation does not support medical necessity.

Services determined to be unproven or not medically necessary are subject to denial
When submitting requests, include evidence supporting medical necessity to mitigate denial risk

Denial Risk

Insufficient Evidence May Lead to Denial

Insufficient or low-quality evidence for a procedure or device (e.g., limited RCTs, small sample sizes, or short follow-up) may lead to a determination of not medically necessary. Additional high-quality, long-term RCT data are typically required to support coverage.

Lack of robust RCTs and long-term outcomes may result in denial
Provide high-quality clinical data when available to support requests

Documentation Required

Contractual and Regulatory Governance on Coverage Decisions

Coverage and authorization decisions must reference applicable federal, state, and contractual requirements. In cases of conflict between this policy and a member’s plan documents or regulatory mandates, the federal/state/contractual requirements govern.

Verify and follow federal, state, and contract-specific benefit requirements prior to providing services
In the event of conflict, federal/state/contract terms supersede this policy

Documentation Required

Required Clinical Trial Details

When prior authorization or coverage is requested for intradiscal procedures or device implantation, include clinical trial details where applicable: study name/identifier, device type/model, annular defect size (when relevant), patient selection criteria, and follow-up outcomes (reherniation, reoperation, pain/function scores, adverse events).

Document study identifiers and relevant trial outcomes (reherniation/reoperation rates, ODI, VAS/NRS)
Report device model, annular defect dimensions, and duration of follow-up

Prior Authorization

Conservative Care Before Intradiscal Procedures

Prior to pursuing intradiscal procedures (e.g., IDET, IDB, PLN, intradiscal injections), documentation should show an adequate trial of conservative care — commonly at least 3 months of nonoperative management — unless contraindicated.

Document ≥ 3 months of conservative therapy (physical therapy, medications, activity modification) for discogenic pain when applicable
If conservative care was not attempted, include rationale or contraindication in the record

IDET (Intradiscal Electrothermal Therapy)Minimally invasive outpatient procedure inserting a flexible catheter with heating element to the annulus to denature collagen, coagulate nerve endings, and 'toughen' disc tissue.

IDB (Intradiscal Biacuplasty)Modification of IDET using bilateral cooled radiofrequency electrodes to create controlled lesions between electrodes while circulating water to cool adjacent tissue.

PIRFT (Percutaneous Intradiscal Radiofrequency Thermocoagulation)Uses a radiofrequency probe placed in the center of the disc (activated ~90 seconds at 70°C) to alter disc biomechanics or destroy nociceptive fibers; similar to IDET but centrally placed probe.

Allogeneic cellular/tissue-based injection — definition of percutaneous injection of cell products

DefinitionPercutaneous injection of allogeneic cellular/tissue-based products: cell therapies injected through the skin into lumbar intervertebral discs to stimulate tissue repair.

Intended effectTo restore or augment nucleus pulposus tissue and stimulate disc repair for degenerative disc disease-related symptoms.

Product examples and evaluationProducts such as Via Disc NP (viable disc allograft) have been evaluated in RCTs and feasibility studies but evidence is limited and inconsistent.

Annular Closure Device (ACD) — definition and example (bone-anchored)

Annular Closure Device (ACD)An implantable device placed at time of limited lumbar discectomy to close large annular defects and potentially reduce recurrent herniation and reoperation.

Example (bone-anchored)Bone-anchored ACDs were studied in an RCT (Thomé et al.) showing reduced recurrent herniation and fewer reoperations versus discectomy alone, though limited by lack of masking and industry sponsorship.

Placement contextIntended for use during primary discectomy in patients with a large annular defect to form a barrier between nucleus and annulus.

Percutaneous intradiscal allogeneic cellular/tissue-based product (VIADISC NP) — definition and evidence note

Product example (VIADISC NP)A viable disc allograft injected percutaneously into the nucleus pulposus intended to restore disc tissue in degenerative disc disease.

Evidence note — RCTsEvolving evidence reviews identified a single fair-quality RCT (Beall et al./VAST) with inconsistent results; some analyses showed responder differences but limitations include crossover and loss to follow-up.

Evidence synthesis conclusionECRI and Hayes concluded evidence is insufficient; additional independent RCTs are needed to validate clinical benefit.

Intradiscal Biacuplasty (IDB) — definition and brief evidence note

Definition — IDB (Intradiscal Biacuplasty)A thermal intradiscal procedure using cooled radiofrequency electrodes to create controlled lesions between electrodes to treat discogenic pain.

Evidence noteSystematic review (Helm et al.) and randomized trials (Desai et al.) report some RCTs showing efficacy for biacuplasty, but overall evidence base is limited by small numbers and methodological issues.

Study limitationsLimitations include small sample sizes, crossover designs, lack of sham controls in some trials, and limited long-term data.

PIRFT — definition noting RCT evidence not supportive

Definition — PIRFTPercutaneous intradiscal radiofrequency thermocoagulation (PIRFT) is intra-annular radiofrequency thermocoagulation performed percutaneously to alter disc biomechanics or destroy nociceptive fibers.

Evidence noteA double-blind RCT (Kvarstein et al. 2009, n=20) found no benefit of PIRFT with the discTRODE probe over sham at 6 months, and no significant between-group differences at 12 months; authors did not recommend intra-annular thermal therapy with the discTRODE probe.

ImplicationRCT evidence does not support routine use of PIRFT with the discTRODE probe; evidence is insufficient for broad clinical adoption.

PIRFT (short label)

Short labelPIRFT (Percutaneous Intradiscal Radiofrequency Thermocoagulation)

Alternate namesAlso called intradiscal electrothermal annuloplasty (IEA), intradiscal radiofrequency thermomodulation, RF annuloplasty.

Use noteIntra-annular thermal therapy applied percutaneously to intervertebral disc to modulate pain fibers or disc biomechanics.

Examples include retrospective cohorts and trials enrolling patients with ≥3 months of symptoms and prior conservative care.

Documentation Required

Document MRI and perioperative findings for ACD placement

For annular closure device placement following discectomy, ensure perioperative imaging (MRI) documents neural compression and a large annular defect meeting the FDA-specified dimensions, and that placement is at a single level between L4 and S1 at the time of primary discectomy.

FDA PMA for Barricaid requires MRI confirmation of neural compression and annular defect dimensions (4–6 mm tall; 6–10 mm wide) following primary discectomy at a single level between L4 and S1.